

University of Groningen

## Regulon of the N-Acetylglucosamine Utilization Regulator NagR in *Bacillus subtilis*

Bertram, Ralph; Rigali, Sebastien; Wood, Natalie; Lulko, Andrzej T.; Kuipers, Oscar P.; Titgemeyer, Fritz

*Published in:*  
Journal of Bacteriology

*DOI:*  
[10.1128/JB.00264-11](https://doi.org/10.1128/JB.00264-11)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2011

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

Bertram, R., Rigali, S., Wood, N., Lulko, A. T., Kuipers, O. P., & Titgemeyer, F. (2011). Regulon of the N-Acetylglucosamine Utilization Regulator NagR in *Bacillus subtilis*. *Journal of Bacteriology*, 193(14), 3525-3536. <https://doi.org/10.1128/JB.00264-11>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Regulon of the *N*-Acetylglucosamine Utilization Regulator NagR in *Bacillus subtilis*<sup>▽†</sup>

Ralph Bertram,<sup>1,2§</sup> Sébastien Rigali,<sup>3§</sup> Natalie Wood,<sup>2</sup> Andrzej T. Lulko,<sup>4</sup>  
Oscar P. Kuipers,<sup>4</sup> and Fritz Titgemeyer<sup>2\*</sup>

*Lehrbereich Mikrobielle Genetik, Eberhard Karls Universität Tübingen, Waldhäuser Strasse 70/8, 72076 Tübingen, Germany*<sup>1</sup>;  
*Lehrstuhl für Mikrobiologie, Institut für Biologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Staudtstrasse 5,  
91058 Erlangen, Germany*<sup>2</sup>; *Centre d'Ingénierie des Protéines, Université de Liège, Institut de Chimie B6,  
Sart-Tilman, B-4000 Liège, Belgium*<sup>3</sup>; and *Molecular Genetics Group, Groningen Biomolecular Sciences and  
Biotechnology Institute, Kluyver Centre for Genomics of Industrial Fermentation, University of  
Groningen, Nijenborgh 7, 9747 AG Groningen, The Netherlands*<sup>4</sup>

Received 24 February 2011/Accepted 6 May 2011

*N*-Acetylglucosamine (GlcNAc) is the most abundant carbon-nitrogen biocompound on earth and has been shown to be an important source of nutrients for both catabolic and anabolic purposes in *Bacillus* species. In this work we show that the GntR family regulator YvoA of *Bacillus subtilis* serves as a negative transcriptional regulator of GlcNAc catabolism gene expression. YvoA represses transcription by binding a 16-bp sequence upstream of *nagP* encoding the GlcNAc-specific EIIBC component of the sugar phosphotransferase system involved in GlcNAc transport and phosphorylation, as well as another very similar 16-bp sequence upstream of the *nagAB-yvoA* locus, wherein *nagA* codes for *N*-acetylglucosamine-6-phosphate deacetylase and *nagB* codes for the glucosamine-6-phosphate (GlcN-6-P) deaminase. *In vitro* experiments demonstrated that GlcN-6-P acts as an inhibitor of YvoA DNA-binding activity, as occurs for its *Streptomyces* ortholog, DasR. Interestingly, we observed that the expression of *nag* genes was still activated upon addition of GlcNAc in a  $\Delta yvoA$  mutant background, suggesting the existence of an auxiliary transcriptional control instance. Initial computational prediction of the YvoA regulon showed a distribution of YvoA binding sites limited to *nag* genes and therefore suggests renaming YvoA to NagR, for *N*-acetylglucosamine utilization regulator. Whole-transcriptome studies showed significant repercussions of *nagR* deletion for several major *B. subtilis* regulators, probably indirectly due to an excess of the crucial molecules acetate, ammonia, and fructose-6-phosphate, resulting from complete hydrolysis of GlcNAc. We discuss a model deduced from NagR-mediated gene expression, which highlights clear connections with pathways for GlcNAc-containing polymer biosynthesis and adaptation to growth under oxygen limitation.

*N*-Acetylglucosamine (GlcNAc) is a nitrogen-containing monosaccharide that constitutes a paramount building block ubiquitously found in the biosphere. GlcNAc-containing polymers, mainly chitin, chitosan, and peptidoglycan, are major constituents of arthropods' exoskeletons, filamentous fungi, and bacterial cell envelopes. Also, the matrix polysaccharides from biofilm of many bacteria consist of linear chains of GlcNAc residues in beta-(1,6) linkage. Considering partial deacetylation of polymeric *N*-acetylglucosamine, the substance is termed polysaccharide intercellular adhesin (PIA), although the abbreviation PNAG (poly-*N*-acetylglucosamine) also is found in the literature (20, 34).

As an amino-monosaccharide, GlcNAc represents a favorable nutrient source for a multitude of microorganisms to feed on, with several studies reporting its high position in the hierarchy of preferred carbon sources (18, 39). Distantly related bacteria, such as streptomycetes, firmicutes, and enterobacteriaceae, commonly use the phosphoenolpyruvate:phospho-

transferase system (PTS) for uptake and phosphorylation of GlcNAc (1, 39, 42, 43, 61). In *Bacillus*, after uptake and concomitant phosphorylation with NagP as a probable PTS EIIBC component (48, 57), GlcNAc-6-phosphate (GlcNAc-6-P) is funneled into the glycolysis shunt after conversion to fructose-6-phosphate (Fru-6-P) by the consecutive action of the enzymes NagA (GlcNAc-6-P deacetylase) (64) and NagB (GlcN-6-P deaminase) (54, 63). On the other hand, when alternative carbon sources are available, GlcNAc is for the most part directed to peptidoglycan synthesis (39). GlcN-6-P is thereby converted into undecaprenol (UDP)-glucosamine, which is incorporated into the cell wall precursor lipid II in a multienzyme process (reviewed in reference 7). Since GlcNAc is exploited for both catabolic and anabolic purposes, its proper utilization should require rigorous and multilevel control, as documented in other model microorganisms, such as *Streptomyces coelicolor* and *Escherichia coli* (43, 45). Moreover, since complete hydrolysis of GlcNAc by the NagA and NagB enzymes generates acetate, ammonia (NH<sub>3</sub>), and Fru-6-P, we anticipate that GlcNAc utilization influences major biological processes, such as glycolysis, the tricarboxylic acid (TCA) cycle, respiration, nucleic acids, nitrogen, and fatty acid metabolism, as well as cell wall biosynthesis.

In this study, we provide a compilation of *in silico*, *in vitro*, and *in vivo* evidence that defines YvoA (also named NagR; see below) as a main transcriptional repressor of genes involved in

\* Corresponding author. Present address: Fachbereich Oecotrophologie, Fachhochschule Münster, Corrensstrasse 25, 48149 Münster, Germany. Phone: 49 251 83-65422. Fax: 49 251 83-65402. E-mail: titgemeyer@fh-muenster.de.

§ R.B. and S.R. contributed equally to this work.

† Supplemental material for this article may be found at <http://jb.asm.org/>.

<sup>▽</sup> Published ahead of print on 20 May 2011.

TABLE 1. Oligonucleotides used in this study

Oligonucleotide	Sequence (5' → 3')
A_lacZ_fw	GCTCAGAATTCTTTTCATTTTATCACTT
A_lacZ_rev	GTTGGATCCGTGCTGATTTTCCCGT
dre_cons_fw	AAACACCTCAaCTGGTCTAGAcCACT
	AGTCTGAAAA
dre_cons_rev	TTTTTCAGACTAGTGgTCTAGACCAGtT
	GAGGTGTTT
dre_nagA_fw	AAACACCTCAGCTGGTCTAGATCACT
	AGTCTGAAAA
dre_nagA_rev	TTTTTCAGACTAGTGATCTAGACCAGC
	TGAGGTGTTT
nagB_fw	TCAAGTCGCGAACACATGTTGTG
	ACAT
nagB_rev	AGCTCCGGATTCAAGGTCTTAATGA
	CGCG
P_lacZ_fw	AATAGAATTCACACGGACCTGGGAA
P_lacZ_rev	AATTGGATCCGACGGCAGAACC
yvnB_fw	GGAAACCGGGACGTCTTGTGCATCA
yvnB_rev	AGCCTCGAGCCCTTTTAAGGATTG
yvoA_ov_fw	GGAACATGCTGACATATGAATAT
	CAAT
yvoA_ov_rev	CATATCTCGCGATCCAGACCAGT
yvoA_fw	CGACCCGGGTATGAATATCAATAAA
	CAATCGCCT
yvoA_rev	ATGTATAGACGTCGCCTCTGTATA
	CGGA

GlcNAc transport and utilization in *Bacillus subtilis*. A recent study revealed the crystal structure of YvoA (49), which belongs to the HutC subfamily of GntR-type transcriptional regulators (50). The ortholog of YvoA in streptomycetes, DasR

(deficient in aerial hyphae and spore formation), has been analyzed in depth: next to its involvement in the control of GlcNAc utilization (52), DasR plays a pivotal role in the regulation of antibiotic synthesis and differentiation (51, 53). Here we aimed to shed light on further common or distinct features of these two regulators. We further intensively characterized the YvoA regulon by combining DNA microarrays and computational prediction of YvoA-binding sites to highlight direct and indirect connections to major regulators of *B. subtilis*. A model of YvoA-dependent pathways is presented and discussed.

## MATERIALS AND METHODS

**Materials and general methods.** Chemicals were purchased from Merck (Darmstadt, Germany), Roth (Karlsruhe, Germany), or Sigma (Munich, Germany) at the highest purity available. Enzymes for DNA restriction and modification were obtained from New England BioLabs (Frankfurt/Main, Germany), Roche (Mannheim, Germany) or PeqLab (Erlangen, Germany) and were used according to the manufacturers' recommendations. Isolation and manipulation of DNA were performed using standard techniques. Oligonucleotides were purchased from MWG-Biotech (Ebersberg, Germany) or biomers.net (Ulm, Germany) and are listed in Table 1. Sequencing was carried out according to the protocol provided by the manufacturer with an ABI Prism 310 genetic analyzer (Applied Biosystems, Weiterstadt, Germany), at MWG-Biotech (Ebersberg, Germany), or at GATC (Constance, Germany).

**Bacterial strains, genetic manipulations, and growth conditions.** Bacterial strains used in this study are listed in Table 2. Standard cloning procedures were applied using *E. coli* DH5 $\alpha$  as a host. *B. subtilis* WH557 (6) served as the parental strain. It chromosomally harbors the *tetR* gene (encoding a tetracycline repressor), enabling repression of *yvoA* in derivative strains (see below). All plasmids constructed in this study were verified by sequencing. Integration of relevant plasmid portions by double homologous recombination into the genome was verified by PCR and sequencing of amplified products. Excision of *lox*-flanked

TABLE 2. Bacterial strains and plasmids used in this study

Strain or plasmid	Relevant characteristics or sequence <sup>a</sup>	Reference or source
<b>Strains</b>		
<i>E. coli</i> DH5 $\alpha$	<i>recA1 endA1 gyrA96 thi relA1 hsdR17</i> (r <sub>K</sub> <sup>−</sup> m <sub>K</sub> <sup>+</sup> ) <i>supE44</i> $\phi$ 80/ <i>lacZ</i> $\Delta$ <i>lacU169</i>	23
<i>E. coli</i> FT1/pLysS	BL21(DE3) $\Delta$ ( <i>ptsHI</i> <i>cr</i> )/pLysS, Km <sup>r</sup>	44
<i>B. subtilis</i> WH557	<i>trpC2 lacA::pt17-tetR-lox66-aphAIII-lox71</i>	6
<i>B. subtilis</i> WH558	<i>trpC2 lacA::pt17-tetR-lox66-aphAIII-lox71 amyE::&gt;InsTet<sup>G+2Cm</sup>&gt;-lacZ</i>	6
<i>B. subtilis</i> FT1	<i>trpC2 lacA::pt17-tetR-lox72</i>	This study
<i>B. subtilis</i> FT2	<i>trpC2 lacA::pt17-tetR-lox72 amyE::dre<sup>nagA</sup>-nagA'-lacZ</i>	This study
<i>B. subtilis</i> FT3	<i>trpC2 lacA::pt17-tetR-lox72 amyE::dre<sup>nagP</sup>-nagP'-lacZ</i>	This study
<i>B. subtilis</i> FT10	<i>trpC2 lacA::pt17-tetR-lox66-aphAIII-lox71 &gt;InsTet<sup>G+2Cm</sup>&gt;-yvoA</i>	This study
<i>B. subtilis</i> FT11	<i>trpC2 lacA::pt17-tetR-lox72 &gt;InsTet<sup>G+2Cm</sup>&gt;-yvoA</i>	This study
<i>B. subtilis</i> FT12	<i>trpC2 lacA::pt17-tetR-lox72 &gt;InsTet<sup>G+2Cm</sup>&gt;-yvoA amyE::dre<sup>nagA</sup>-nagA'-lacZ</i>	This study
<i>B. subtilis</i> FT13	<i>trpC2 lacA::pt17-tetR-lox72 &gt;InsTet<sup>G+2Cm</sup>&gt;-yvoA amyE::dre<sup>nagP</sup>-nagP'-lacZ</i>	This study
<i>B. subtilis</i> FT20	<i>trpC2 lacA::pt17-tetR-lox66-aphAIII-lox71 yvoA::cat</i>	This study
<i>B. subtilis</i> FT21	<i>trpC2 lacA::pt17-tetR-lox72 yvoA::cat</i>	This study
<i>B. subtilis</i> FT22	<i>trpC2 lacA::pt17-tetR-lox72 yvoA::cat amyE::dre<sup>nagA</sup>-nagA'-lacZ</i>	This study
<i>B. subtilis</i> FT23	<i>trpC2 lacA::pt17-tetR-lox72 yvoA::cat amyE::dre<sup>nagP</sup>-nagP'-lacZ</i>	This study
<b>Plasmids</b>		
pAC7	Vector for integration into <i>amyE</i> of <i>B. subtilis</i> , pBR322 derivative, Ap <sup>r</sup> Cm <sup>r</sup>	66
pAC7-nagA	<i>dre<sup>nagA</sup>-nagA'-lacZ</i> , Ap <sup>r</sup> Cm <sup>r</sup> , pAC7 derivative	This study
pAC7-nagP	<i>dre<sup>nagP</sup>-nagP'-lacZ</i> , Ap <sup>r</sup> Cm <sup>r</sup> , pAC7 derivative	This study
pCrePA	P <sub>pagA</sub> - <i>cre</i> , thermosensitive, expression of <i>cre</i> , Ap <sup>r</sup> Erm <sup>r</sup>	46
pRAB1	P <sub>pagA</sub> - <i>cre</i> , thermosensitive, expression of <i>cre</i> , Ap <sup>r</sup> Cm <sup>r</sup>	29
pWH1935-2 <sup>Cm</sup>	InsTet <sup>G+2Cm</sup> , pUC19 derivative, Ap <sup>r</sup> Cm <sup>r</sup>	6
pWH1935-2 <sup>Cm</sup> NA	>InsTet <sup>G+2Cm</sup> >-yvoA, pWH1935-2 <sup>Cm</sup> derivative	This study
pWH1935-2 <sup>Cm</sup> NB	yvoA::cat, pWH1935-2 <sup>Cm</sup> derivative	This study
pET-3c	Ap <sup>r</sup> , P <sub>T7</sub>	Novagen
pET-3c-yvoA	P <sub>T7</sub> -yvoA, pET-3c derivative	This study

<sup>a</sup> Angle brackets denote the promoter direction in InsTet<sup>G+1a</sup> or InsTet<sup>G+2Cm</sup>. Abbreviations: Ap, ampicillin; Cm, chloramphenicol; Km, kanamycin; superscript r, resistant.

resistance cassettes from *B. subtilis* chromosomes was achieved using the Cre recombinase expression plasmid pCrePA (46) or pRAB1 (29) as described previously (5). Briefly, strains subjected to Cre treatment were transformed with either of the two plasmids and initially incubated at 30°C (permissive for the plasmids' thermosensitive origins of replication) to allow cre expression. A temperature shift to 37°C with further incubation for 1 or 2 days resulted in plasmid loss. The results of site-specific recombination by Cre were checked by PCR, and the concomitant reinstated antibiotic sensitivity of respective strains was verified by an inability to grow on selective media. Cells were generally grown in LB medium unless stated otherwise. Media contained the following antibiotics, where appropriate: ampicillin (Ap) (100 mg/liter for *E. coli*), kanamycin (Km) (60 mg/liter for *E. coli* or 15 mg/liter for *B. subtilis*), and chloramphenicol (Cm) (25 mg/liter for *E. coli* or 5 mg/liter for *B. subtilis*). (Liquid) cultures were incubated (shaking) at 37°C unless stated otherwise.

**Phylogeny analysis.** GntR/HutC subfamily regulators of *B. subtilis* 168 were used as a training set to generate phylogenetic trees performed on the Phylogeny.fr platform (16) using the "One click" mode, which provides ready-to-use pipeline chaining programs: MUSCLE for multiple alignment, Gblocks for automatic alignment curation, PhyML for tree building, and TreeDyn for tree drawing.

**Computational prediction of YvoA-binding sites.** YvoA-binding sites upstream of *nagP* (*dre<sup>nagP</sup>*; ATTGGTATAGTCACT) and upstream of the *nagAB-yvoA* locus (*dre<sup>nagA</sup>*; GCTGGTCTAGTCACT) of *B. subtilis* were used to search similar sequences upstream of *nagP* and *nagA* orthologues in *Bacillus* species using the PREDetector software program (24). This list of 18 *dre* sites (see Table S1 in the supplemental material) was used to generate a position weight matrix (named NagR 2011) for NagR (YvoA) regulon prediction in *Bacillus* species.

**Production and purification of YvoA in *E. coli*.** The plasmid pET-3c-*yvoA* (see Table 2) was constructed for overexpression of YvoA by cloning *yvoA* amplified with the primers *yvoA\_ov\_fw* and *yvoA\_ov\_rev* into pET-3c (Novagen) via NdeI/BamHI. Native YvoA was purified using a protocol and the same conditions established for purification of TetR (19). Briefly, *E. coli* FT1/pLysS (44) was transformed with pET-3c-*yvoA*, and T7-polymerase-dependent *yvoA* transcription was induced by isopropyl-β-D-thiogalactopyranoside (IPTG). After ultracentrifugation of crude cell extract, the supernatant was subjected to cation exchange chromatography and subsequent size fractionation. The concentration was determined by measuring the fluorescence of the solution at  $\lambda = 280$  nm.

**EMSA.** To detect binding of purified YvoA to DNA, electrophoretic mobility shift assays (EMSA) were conducted as follows. First, the complementary oligonucleotides *dre\_nagA\_fw* and *dre\_nagA\_rev* or *dre\_cons\_fw* and *dre\_cons\_rev*, respectively, were hybridized. To this end, equimolar amounts of each of two single-stranded oligonucleotides were mixed, heated at 96°C for 5 min, and allowed to cool to room temperature within 2 h, yielding the double-stranded 36-bp fragments *dre<sup>nagA</sup>* and *dre<sup>cons</sup>*. YvoA was added to the DNA fragments at indicated amounts and incubated for 10 min at room temperature in complex buffer (50 mM Tris-HCl [pH 7.5], 20 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol [DTT]). Assumed inducers of YvoA were added to final concentrations of 100 mM where applicable. Reaction mixtures were subjected to electrophoresis on a 10% polyacrylamide gel at 50 V in TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA; pH 8.3 to 8.5), and DNA was detected by ethidium bromide staining.

**Construction of *B. subtilis* strains bearing chromosomally inactivated or repressed *yvoA*.** A 296-bp fragment containing the 3' part of the *nagB* gene (upstream of *yvoA*) including its stop codon was obtained using the primers *nagB\_fw* and *nagB\_rev*. This fragment was cloned into pWH1935-2<sup>Cm</sup> (6) via PciI/BspEI to yield pWH1935-2<sup>Cm</sup>N. A 493-bp fragment containing a 3' portion of the *yvnB* gene (downstream of *yvoA*) was obtained with primers *yvnB\_fw* and *yvnB\_rev*, digested with the enzymes AatII and XhoI, and inserted into the likewise restricted pWH1935-2<sup>Cm</sup>N, yielding plasmid pWH1935-2<sup>Cm</sup>NB. *B. subtilis* WH557 (6), which served as a parental strain (*yvoA* positive control), was transformed with the AhdI-linearized plasmid pWH1935-2<sup>Cm</sup>NB by a standard procedure (27). The resulting strain was designated FT20 (*ΔyvoA*). Treatment of strain FT20 with the Cre recombinase gave rise to the marker-free strain FT21. The Km resistance gene was also removed by the same procedure from the parental strain *B. subtilis* WH557 to yield strain FT1.

In order to provide an *yvoA* repression mutant in addition to the *yvoA* knock-out strain, we placed *yvoA* under the control of the TetR-controlled promoter *P<sub>xyI/tet</sub>* (21). For this purpose, a 712-bp PCR product comprising almost the entire *yvoA* gene (obtained with primers *yvoA\_fw* and *yvoA\_rev*) was inserted into pWH1935-2<sup>Cm</sup>N via AatII/XmaI. The resulting plasmid, pWH1935-2<sup>Cm</sup>NA, was AhdI linearized and used to transform *B. subtilis* WH557. The resulting strain was designated FT10 (*P<sub>xyI/tet</sub>yvoA*), and the further steps required to obtain the marker-free strain FT11 were identical to those conducted to generate FT20 (see above).

**Construction of *B. subtilis* β-galactosidase reporter strains to monitor *nagA* and *nagP* promoter activity.** Plasmids for the construction of reporter strains were constructed as follows. Fragments of *nagA* or *nagP* (including respective *dre* sites within the upstream region and 33 or 20 codons of the genes, respectively) were amplified with primers *A\_lacZ\_fw* and *A\_lacZ\_rev* or *P\_lacZ\_fw* and *P\_lacZ\_rev*, respectively. Fragments were cloned into plasmid pAC7 (66) via EcoRI/BamHI to obtain pAC7-*nagA* and pAC7-*nagP*, which encode N-terminal translational fusions of NagA or NagP with β-galactosidase (β-Gal). Strains FT1 (parental strain), FT11 (*P<sub>xyI/tet</sub>yvoA*), and FT21 (*ΔyvoA*) were transformed with plasmid pAC7-*nagA* or pAC7-*nagP*, and chromosomal integration into the *amyE* loci was verified using starch agar plates. The obtained strains were designated FT2, FT12, and FT22 in cases of encoded NagA'-β-gal fusions and FT3, FT13, and FT23 in cases of encoded NagP'-β-gal fusions (Table 2).

**Enzyme assays.** *nagB*-encoded GlcN-6-P isomerase activity was measured in a coupled assay. *B. subtilis* cells were cultivated in CSK minimal medium (36), supplemented with a final concentration of 0.2% (wt/vol) GlcNAc, where appropriate, to an optical density at 600 nm (OD<sub>600</sub>) of about 0.8. Cells were broken by sonication, and 250 μl of soluble protein extract, adjusted to 1 μg/μl in ZAP buffer (10 mM Tris-HCl, pH 8, 200 mM NaCl, 5 mM DTT) was used. The reaction mixture additionally contained 1 mM GlcN-6-P, 0.2 mM NADP<sup>+</sup>, 230 mM Na<sub>2</sub>HPO<sub>4</sub>, 230 mM NaH<sub>2</sub>PO<sub>4</sub>, 3 U of phosphoglucose isomerase, and 2 U Glc-6-P dehydrogenase (both from Sigma, Munich, Germany). Reduction of NADP<sup>+</sup> as a means for NagB activity was determined by measuring the rate of change at *E*<sub>340</sub>. The specific activity was calculated using the following formula: specific activity = dA/min · 1,000/6.3 · Pr, whereby dA denotes the change in *E*<sub>340</sub> and Pr denotes the protein concentration (mg/ml). Quantification of β-gal activity of mid-log-growth-phase cells cultured in LB medium supplemented with different antibiotics and/or GlcNAc, where appropriate, was performed according to the method of Miller (38) and adapted as described previously (26).

**Microarray experiments.** Transcriptome analyses were conducted with four biological replicates (each) of strains WH558 (wild-type [wt] *yvoA*) and FT20 (*ΔyvoA*), which harbor identical resistance markers. Overnight cultures of cells grown in baffled Erlenmeyer flasks containing 20 ml tryptone-yeast extract (TY) broth with kanamycin and chloramphenicol but without GlcNAc were freshly diluted into identically prepared flasks to an OD<sub>600</sub> of ~0.05. Cultures were harvested in mid-log growth phase at OD<sub>600</sub> values between 0.71 and 0.79. The further steps, including breaking of cells, RNA preparation, quantity and quality control, synthesis, labeling and purification of cDNA, hybridization, microarray handling, and data evaluation, were taken as described previously (33). Data with Cyber-T (Bayes) *P* values of <0.01 were judged significant, and genes regulated by a factor of at least 2 are listed in Table 3.

## RESULTS AND DISCUSSION

**In silico identification of YvoA as presumed *N*-acetylglucosamine utilization regulator in *Bacillus* species.** A role of YvoA in regulating GlcNAc metabolism in *Bacillus* species was predicted from a BLASTP analysis of the *S. coelicolor* GlcNAc utilization regulator DasR (KEGG identifier [ID] SCO5231). The highest similarity to DasR was indeed shown by the GntR/HutC subfamily (50) transcriptional regulator YvoA, with a sequence identity of 40% and a similarity value of 60%. Phylogeny analyses, either performed on the entire protein sequence or limited to the DNA-binding domain (not shown) of all seven GntR/HutC regulators from *B. subtilis* and DasR from *S. coelicolor*, suggested that DasR and YvoA, together with GmuR, the glucomannan utilization repressor (56), had emerged from a common ancestor (Fig. 1). The predisposition of YvoA and DasR to share similar DNA-binding properties was recently confirmed by Resch and collaborators, who showed that YvoA was able to bind with high affinity to the DasR responsive element (*dre*)-like sequence (ATTGGTATA GATCACT) located at 66 nucleotides [nt] upstream of *nagP*, coding for the GlcNAc-specific PTS EIIBC component in *B. subtilis* (49).

Examination of gene organization around the *yvoA* locus also provided unambiguous indications for its presumed impli-



TABLE 3. Transcriptome analysis for definition of YvoA (NagR) regulon in *B. subtilis*<sup>a</sup>

Category and KEGG no.	Name(s)	Function	Expression, $\Delta yvoA$ /wt	cis-acting element	Pathway	Regulon(s)	Reference(s)
Genes upregulated in the $\Delta yvoA$ mutant compared to parental strain <i>B. subtilis</i> WH558							
BSU07700	<i>nagP</i>	PTS N-acetylglucosamine-specific enzyme IICB component	+4.55	YvoA	GlcNAc metabolism	YvoA	This study
BSU35010	<i>nagA</i>	N-Acetylglucosamine-6-phosphate deacetylase	+2.53	YvoA	GlcNAc metabolism	YvoA	This study
BSU04300	<i>ydaM</i>	Putative glycosyltransferase associated to biofilm formation	+3.95	—	Biofilm formation	—	—
BSU33950	<i>cggR</i>	Central glycolytic genes repressor	+3.49	CggR	Glycolysis	CggR	31
BSU15510	<i>pyrA4</i>	Carbamoyl phosphate synthase small subunit	+2.85	PyrR	Pyrimidine biosynthesis	PyrR	25
BSU15520	<i>pyrA8</i>	Carbamoyl phosphate synthase large subunit	+3.44	PyrR	Pyrimidine biosynthesis	PyrR	25
BSU15500	<i>pyrC</i>	Dihydroorotate	+2.35	PyrR	Pyrimidine biosynthesis	PyrR	25
BSU15540	<i>pyrD</i>	Dihydroorotate dehydrogenase 1B	+2.30	PyrR	Pyrimidine biosynthesis	PyrR	25
BSU15560	<i>pyrE</i>	Orotate phosphoribosyltransferase	+2.21	PyrR	Pyrimidine biosynthesis	PyrR	25
BSU15550	<i>pyrF</i>	Orotidine 5'-phosphate decarboxylase	+2.23	PyrR	Pyrimidine biosynthesis	PyrR	25
BSU15530	<i>pyrK</i>	Dihydroorotate dehydrogenase electron transfer subunit	+2.24	PyrR	Pyrimidine biosynthesis	PyrR	25
BSU02700	<i>lip<sub>1</sub> exsA</i>	Secreted triacylglycerol alkaliphilic lipase	+2.01	—	Triacylglycerol metabolism	—	15
BSU37210	<i>ywjC</i>	Hypothetical protein	+2.60	—	Unknown function	—	—
Genes downregulated in the $\Delta yvoA$ mutant compared to parental strain <i>B. subtilis</i> WH558							
BSU37310	<i>fnr</i>	Fnr, fumarate nitrate reductase regulator	-2.63	Fnr	Anaerobic redox regulator	Fnr	14
BSU37290	<i>arfM</i>	Anaerobic respiration and fermentation modulator	-4.10	Fnr	Anaerobic genes regulator	Fnr/ResDE	35
BSU37300	<i>ywiC</i>	Unknown, putative integral inner membrane protein	-4.13	Fnr	Unknown	—	—
BSU37280	<i>narG</i>	Nitrate reductase (alpha subunit)	-2.70	Fnr	Nitrate reduction	Fnr	14
BSU37270	<i>narH</i>	Nitrate reductase (beta subunit)	-3.13	Fnr	Nitrate reduction	Fnr	14
BSU37250	<i>narI</i>	Nitrate reductase assembling factor	-3.17	Fnr	Nitrate reduction	Fnr	14
BSU37260	<i>narJ</i>	Nitrate reductase (gamma subunit)	-2.62	Fnr	Nitrate reduction	Fnr	14
BSU37320	<i>narK</i>	Nitrite extrusion permease	-3.84	Fnr	Nitrate extrusion	Fnr	14
BSU14160	<i>ykuO</i>	Hypothetical protein	-5.13	Fnr	Flavodoxins for NO production	Fnr/Fur	3, 47
BSU14170	<i>ykuP</i>	Short-chain flavodoxin	-3.99	Fnr	Flavodoxins for NO production	Fnr/Fur	3, 47
BSU32000	<i>dhbA</i>	2,3-Dihydroxybenzoate-2,3-dehydrogenase	-4.26	Fur	Siderophore (Bacillibactin) synthesis	Fnr/Fur	3, 47
BSU31970	<i>dhbB</i>	Isochorismatase	-3.58	Fur	Siderophore (Bacillibactin) synthesis	Fnr/Fur	3, 47
BSU31990	<i>dhbC</i>	Isochorismate synthase	-2.99	Fur	Siderophore (Bacillibactin) synthesis	Fnr/Fur	3, 47
BSU31980	<i>dhbE</i>	2,3-Dihydroxybenzoate-AMP ligase	-3.64	Fur	Siderophore (Bacillibactin) synthesis	Fnr/Fur	3, 47
BSU31960	<i>dhbF</i>	Siderophore 2,3-dihydroxybenzoate-glycine-threonine trimeric ester	-4.91	Fur	Siderophore (Bacillibactin) synthesis	Fnr/Fur	3, 47
BSU38740	<i>cydC</i>	ABC transporter (ATP-binding) for cytochrome <i>bd</i> function	-3.32	YdiH	Low oxygen tension	Fnr/Fur/YdiH	59
BSU22070	<i>xpt</i>	Xanthine phosphoribosyltransferase	-2.59	—	Purine biosynthesis	—	—
BSU02420	<i>ybgH, glnT</i>	Glutamine transporter	-2.39	GlnL	Gln/Glu metabolism	GlnL	58
BSU01640	<i>ybbB, Btr</i>	Bacillibactin transport regulator	-2.38	Fur	Bacillibactin uptake	Fur	3
BSU37410	<i>albE</i>	Putative hydrolase involved in subtilisin production	-2.02	AbrB/ResD	Antilisterial bacteriocin (subtilisin) production	ResD/Fnr/AbrB/Spo0A	69
BSU37420	<i>albF</i>	Putative peptidase involved in subtilisin production	-2.37	AbrB/ResD	Antilisterial bacteriocin (subtilisin) production	ResD/Fnr/AbrB/Spo0A	69
BSU01630	<i>feuA</i>	Iron hydroxamate-binding lipoprotein	-2.27	Fur	Siderophore uptake	Fur	3
BSU01620	<i>feuB</i>	Iron-uptake protein	-2.00	Fur	Siderophore uptake	Fur	3
BSU01610	<i>feuC</i>	Iron-uptake protein	-2.02	Fur	Siderophore uptake	Fur	3
BSU32940	<i>yusV</i>	Iron(III)-siderophore transporter	-2.10	Fur	Siderophore uptake	Fur	3
BSU33320	<i>fluD</i>	Ferrichrome ABC transporter	-2.04	Fur	Siderophore uptake	Fur	3
BSU39610	<i>yxeB</i>	ABC transporter (ferrioxamine binding lipoprotein)	-2.21	Fur	Siderophore uptake	Fur	3
BSU04530	<i>ydbN</i>	Hypothetical protein	-2.02	Fur	Unknown function	Fnr/Fur	3, 47
BSU32030	<i>ywiG, bioYB</i>	Putative biotin transporter	-3.77	—	—	—	—

BSU36550	<i>spoIIQ</i>	Forespore protein required for alternative engulfment	−2.21	—	Spore engulfment	—	30
BSU34140	<i>yvFM, ganQ</i>	Arabinogalactan oligomer permease	−2.20	—	Arabinogalactan metabolism	—	—
BSU30280	<i>amyD</i>	Carbohydrate ABC transporter	−2.16	—	Carbohydrate metabolism	—	—
BSU19310	<i>dhaS</i>	Putative aldehyde dehydrogenase	−2.12	—	Unknown	—	—
BSU11990	<i>yjdB</i>	Hypothetical protein	−2.01	—	Unknown function	—	—

<sup>a</sup> —, *cis*-acting element, *trans*-acting regulator, pathway, or regulon unknown. Genes listed exhibited differential expression by a factor of at least 2, with a Cyber-T (Bayes) *P* value of <0.01 (see Materials and Methods), between WH558 and FT20 grown without GlcNAc.




FIG. 1. Phylogeny analysis of GntR/HutC subfamily regulators of *B. subtilis* and DasR from *S. coelicolor*. Proteins used as a training set to generate the tree are as follows: (i) GmuR, the regulator of glucomannan catabolism (YdhQ; NP\_388466) (56), (ii) FrIR, possibly involved in regulation of utilization of sugar amines according to the SubtiWiki database (YurK; NP\_391136) (28), (iii) YbgA, which presumably represents a repressor of the *gamAP* operon encoding glucosamine catabolism enzymes (NP\_388119) (48), (iv) TreR, the trehalose utilization repressor (NP\_388663) (60), (v) YmFC (NP\_389563), (vi) YdK (NP\_391893), (vii) YvoA (NP\_391383), and (viii) DasR, the GlcNAc utilization regulator from *S. coelicolor* (NP\_629378) (51). The phylogenetic tree was generated via the Phylogeny.fr platform (16). Note that YvoA and DasR emerge together from a common ancestor.

cation in GlcNAc utilization (62). Indeed, in *yvoA*-containing *Bacillus* species (except *Bacillus clausii*), this gene is the third element of a putative tricistronic operon that includes in the first two positions *nagA* (the GlcNAc-6-P deacetylase gene) and *nagB*, which encodes the enzyme that catalyzes the deamination and isomerization of GlcNAc-6-P to Fru-6-P (Fig. 2). Interestingly, other GlcNAc metabolism-related genes are located in the vicinity of the *nagAB-yvoA* locus in other *Bacillus* species and therefore are presumably part of the YvoA regulon. This is the case for *nagP*, which is the fifth element of the putative *nagAB-yvoA* operon in *Bacillus licheniformis* and is positioned divergently from *nagA* in *Bacillus halodurans*, *Bacillus pseudofirmus*, and *Bacillus megaterium* (Fig. 2). In addition, *murQ*, which encodes an *N*-acetylmuramic acid-6-phosphate (MurNAc-6-P) etherase converting MurNAc-6-P to GlcNAc-6-P and D-lactate, is located between *yvoA* and *nagP* in *B. licheniformis*. The observed synteny of *yvoA* loci in *Bacillus* species thus strengthens the presumed role of YvoA in controlling key genes of the GlcNAc metabolism.

**Identification of new YvoA-binding sequences and glucosamine-6-phosphate as YvoA DNA-binding activity modulator.** The YvoA binding site verified by Resch and colleagues—AT TGGTATAGATCACT, termed *dre<sup>nagP</sup>* (49)—fits 13 out of the 16 nucleotides of the consensus of the DasR responsive element *dre<sup>Streptomyces</sup>* (AGTGGTCTAGACCACT) deduced from previous *S. coelicolor* studies (11). Exploiting the PREDetector software program (24) to identify further putative YvoA binding sites revealed another DNA sequence (GC TGGTCTAGATCACT) that also fits 13 out of the 16 nucleotides of *dre<sup>Streptomyces</sup>*. We designated this site, located at




FIG. 2. Synteny of the *yvoA* locus in *Bacillus* species. Gene organization around the various *yvoA* loci was deduced from the complete genome sequences retrieved from NCBI. Note the integration of *murQ* and *nagP* into the putative *nagAB-yvoA* operon in several species. Abbreviations: *nagA*, GlcNAc-6-P deacetylase gene; *nagB*, GlcN-6-P isomerase gene; *nagP*, encoding sugar phosphotransferase EIIIC component for GlcNAc transport and phosphorylation; *murQ*, MurNAc-6-P etherase gene. Black rectangles upstream of *nagA* orthologues represent identified *dre*-like sequences putatively bound by YvoA. *Bsu*, *B. subtilis*; *Bpu*, *B. pumilis*; *Bli*, *B. licheniformis*; *Bam*, *B. amyloliquefaciens*; *Bme*, *B. megaterium*; *Bps*, *B. pseudofirmus*; *Bha*, *B. halodurans*; *Bcl*, *B. clausii*; *Bse*, *B. selenitireducens*.

position  $-70$  in the upstream region of the *nagAB-yvoA* region, *dre<sup>nagA</sup>*. We could identify similar *dre* sequences upstream of the *nagAB* or *nagP* gene in all *Bacillus* species which possess an YvoA ortholog and for which genome data are available (see Table S1 in the supplemental material).

In order to confirm the interaction of YvoA with the newly

found *dre*-like motif, we used DNA fragments containing *dre<sup>nagA</sup>* and *dre<sup>Streptomyces</sup>* for qualitative binding assays with purified YvoA. As depicted in Fig. 3A, migration of *dre<sup>nagA</sup>* fragment during electrophoresis was clearly retarded in the presence of YvoA (which also held true for EMSA with *dre<sup>Streptomyces</sup>*; not shown). In order to determine which low-




FIG. 3. YvoA DNA-binding abilities. (A) EMSA displaying binding of YvoA to *dre<sup>nagA</sup>* and identification of GlcN-6-P as a DNA-binding inhibitor. Twenty picomoles of double-stranded DNA fragment was electrophoresed alone (lane 1) or after incubation with 10 pmol of YvoA monomers (lane 2) and a final concentration of 100 mM GlcNAc (lane 3), GlcNAc-6-P (lane 4), GlcN-6-P (lane 5), or GlcN (lane 6), respectively. (B) Weblogo representation of *Streptomyces* and *Bacillus* consensus *dre* sites. Note main differences at positions 2 (G  $\rightarrow$  T), 7 (C  $\rightarrow$  A), and 13 (C  $\rightarrow$  A) of the *dre* sites. Weblogo representation of *dre<sup>Bacillus</sup>* was generated with all YvoA-binding sequences upstream on *Bacillus* species *nagA* and *nagP* genes (see Table S1 in the supplemental material), and the Weblogo *dre<sup>Streptomyces</sup>* representation was generated with *dre* sites identified upstream of the *S. coelicolor* *nagB*, *nagA*, *dasA* (12), and PTS genes involved in GlcNAc uptake.




FIG. 4. Schematic representation of selected strains constructed in this study. Parent strain WH557 bears an unaffected *yvoA* gene and a chromosomally integrated *tetR* gene. FT1 is isogenic to WH557 but lacks the kanamycin resistance gene *aphAIII* after excision by Cre recombinase. Strains FT10 and FT20 are derived from WH557 and were also treated with Cre to yield FT11 and FT21, respectively. FT2, FT3, FT12, FT13, FT22, and FT23 are constructs allowing reporter gene assays of the *nagA* or the *nagP* promoter(s).

molecular-weight effector(s) could modulate the DNA-binding capability of YvoA, the regulator was incubated with *dre<sup>nagA</sup>* in the presence of each of the four different aminosugar compounds GlcNAc, GlcNAc-6-P, GlcN-6-P, and GlcN. Subsequent EMSA analyses resulted in the observation that among the tested compounds only GlcN-6-P was able to abolish YvoA binding to *dre<sup>nagA</sup>* (Fig. 3A). GlcN-6-P was also reported to inhibit the DNA-binding capability of DasR in *S. coelicolor* (51), whereas isothermal calorimetry titration measurements for binding of GlcN-6-P to YvoA conducted by Resch and colleagues had been inconclusive (49). Interestingly, the crystal structure in this study had been solved for YvoA in complex with GlcNAc-6-P, which had not appeared to interfere with *dre* binding in EMSA. These data fit a model that suggests that upon GlcNAc-6-P-binding, only one half-side of the YvoA dimer is detached from the *dre* sequence, which, however, does not abolish the YvoA-DNA complex. It is plausible that GlcN-6-P could cause a different allosteric mechanism through which effector binding modulates DNA affinity. Depending on the intracellular concentrations of the various aminosugar com-

pounds (GlcNAc, GlcNAc-6-P, or GlcN-6-P), the effect on YvoA DNA binding would be different with appropriate expression adjustment of YvoA-dependent genes. Compilation of known and predicted YvoA-binding sites (see the table in the supplemental material) led us to identify ATTGGTATA GACAAC as an YvoA consensus sequence (*dre<sup>Bacillus</sup>*) which is not a perfect palindrome and differs from the *Streptomyces dre* consensus sequence at positions 2 (G  $\rightarrow$  T), 7 (C  $\rightarrow$  A), and 13 (C  $\rightarrow$  A). Graphical representations of *Streptomyces* and *Bacillus dre* sites were generated using the Weblogo software application and are displayed in Fig. 3B.

**YvoA represses expression of the N-acetylglucosamine-induced genes *nagP*, *nagA*, and *nagB*.** To gain insights into the regulatory role of YvoA in *B. subtilis* *in vivo*, we first constructed two new strains on the basis of the *yvoA*-proficient strain WH557 (Fig. 4). To enable artificial repression of *yvoA*, strain FT10 was constructed, in which we placed *yvoA* expression under the control of the TetR-controlled promoter  $P_{xyl/tet}$  (6, 21). In addition, FT20, which bears a complete *yvoA* deletion, was generated. In order to test the assumption of YvoA-






FIG. 5. (A) NagB assay. The activity of the glucosamine-6-phosphate isomerase NagB was assayed in strains with either WH558 (*yvoA* proficient), FT20 ( $\Delta yvoA$ ), or FT10 (repressed *yvoA*). White or black bars denote specific activities of cells grown without or with GlcNAc, respectively. The error bars represent the standard deviations of biological triplicate determinations. (B)  $\beta$ -Galactosidase assays of *nagA'*-*lacZ* and *nagP'*-*lacZ* fusions. Transcription of *nagA* (left part) and *nagP* (right part) was indirectly assayed in strains with either pristine *yvoA* (FT2 and FT3) or  $\Delta yvoA$  (FT22 and FT23) or transcriptionally repressed *yvoA* (FT12 and FT13) by means of translational fusions with *lacZ*. White or black bars denote specific activities of cells grown without or with GlcNAc, respectively. The error bars represent the standard deviations of biological triplicate determinations.

dependent regulation of *nagA*, *nagB*, and *nagP* *in vivo*, the activity of NagB, catalyzing the deamination and isomerization of GlcN-6-P to Fru-6-P (63), was quantified using *B. subtilis* FT10 ( $P_{xyl/tet}$ -*yvoA*), FT20 ( $\Delta yvoA$ ), and WH558 (wt *yvoA*, comparable to the parental strain, WH557, but with a kanamycin resistance marker identical to that of FT10 and FT20). Observed NagB activities, displayed in Fig. 5A, were all elevated among the strains with deleted or repressed *yvoA* in comparison to findings for WH558, suggesting a transcriptional repressor role for YvoA. According to expectations, WH558 cells displayed higher values upon growth with GlcNAc, apparently due to release of YvoA from *dre<sup>nagA</sup>*. Interestingly, however, higher NagB activities in the presence of GlcNAc were also observed for strains FT10 and FT20, which can be expected to produce only minute amounts of YvoA or no YvoA at all, respectively (see below).

To further validate regulation of catabolic *nag* genes, vectors carrying translational *lacZ* fusions to *nagA* or *nagP* were constructed. After elimination of the kanamycin resistance markers from WH557, FT10, and FT20 by Cre recombinase, the plasmids were chromosomally integrated into the obtained strains FT1 (wt *yvoA*), FT11 ( $P_{xyl/tet}$ -*yvoA*), and FT21 ( $\Delta yvoA$ ). The obtained descendants bearing the *nagA'*-*lacZ* fusion were designated FT2, FT12, and FT22, and those with *nagP'*-*lacZ* were termed FT3, FT13, and FT23 (Fig. 4). Levels of  $\beta$ -Gal in these strains were found to be very low, but the same tendency as in NagB assays was still observed, i.e., higher activities when *yvoA* was inactivated by deletion or repression (Fig. 5B). Moreover, *nagA* and *nagP* promoters' activities were still higher when strains were grown in the presence of GlcNAc, as previously observed in NagB assays (Fig. 5A). Since GlcNAc-dependent regulation was not abolished in strains with low amounts of or no YvoA, we anticipate the coexistence of (an) other system(s) of *nag* genes' control. Early articles described

that the activity of enzymes involved in GlcNAc transport, deamination, deacetylation and isomerization was elevated in the presence of the aminosugar but decreased under glucose conditions (4, 10, 39). These observations give reason to assume a glucose carbon catabolite repression system (reviewed in reference 22) of higher hierarchy than a GlcNAc-specific mode of control. In fact, *nagAB* has been described to be repressed by Glc, with possible involvement of the pleiotropic regulator CcpA (8).

**Expression profiling using DNA microarrays for definition of the YvoA regulon in *B. subtilis*.** Changes in the transcriptome of *yvoA* mutant strain FT20 compared to that of the *B. subtilis* parental strain WH558 were analyzed using whole-genome DNA microarrays and total RNA of cells harvested in mid-log growth phase. Table 3 lists genes the mRNA levels of which were significantly altered by a factor of at least 2 (further transcriptome data are listed in Table S2 in the supplemental material), and Fig. 6 summarizes main YvoA-related pathways. Three different groups of *yvoA*-dependent genes were distinguished by their expression patterns. The first group consists of genes that are repressed by YvoA and that have a significant *dre* site within their upstream region. The second and third groups consist of genes repressed or induced by YvoA, respectively, but with no obvious YvoA-binding site detected.

Group 1 includes only *nagP* and *nagA*, with a 4.6- and 2.5-fold upregulation in the *yvoA* mutant background compared to the parental strain, respectively. The distribution of predicted YvoA-binding sites was limited to *nagP* and the *nagAB-yvoA* locus within the *B. subtilis* chromosome, which contrasts with the situation in streptomycetes, where hundreds of *dre* sites for the YvoA ortholog DasR have been identified in the *S. coelicolor* genome (S. Rigali, personal communication). The limited number of predicted *dre* sites in *B. subtilis* also suggests that YvoA might be a less-prominent regulator than DasR and may




FIG. 6. Summary of pathways influenced by YvoA (NagR). Genes (or their deduced proteins) that possess an YvoA-binding sequence within their upstream region are represented in black. Final end products of complete GlcNAc hydrolysis are highlighted in orange, i.e., acetate, NH<sub>3</sub>, and Fru-6-P. Arrows in green or red indicate genes, the expression of which is up- or downregulated, respectively, in strain FT20 ( $\Delta yvoA$  mutant) compared to expression in the parental strain *B. subtilis* WH558. Metabolic fluxes are represented by arrows; lines with T ends indicate transcriptional repression. "+" and "-" values indicate the expression ratio between strains FT20 and WH558 deduced from microarray analyses (for a complete set of values and protein functions, see Table 3).

fulfill more confined tasks, i.e., the uptake and subsequent utilization of GlcNAc. However, *yvoA* deletion results in the modulation of the expression of many other important genes (Table 3; also see below). The absence of *dre* sites within their upstream region suggests that the *yvoA* deletion may thus indirectly alter their expression, possibly by affecting intracellular levels of Fru-6-P, acetate, and NH<sub>3</sub>, which are the final products of complete GlcNAc catabolism and are key molecules involved in numerous biological processes. At this stage, based upon the compilation of *in silico*, *in vitro*, and *in vivo* data obtained in this study, it seems timely to rename YvoA "NagR," for *N*-acetylglucosamine utilization regulator.

Group 2 contains genes upregulated in strain FT20 but

without exhibiting significant NagR-binding sites. *ydaM* (BSU04300) is 4.0-fold-upregulated in the *nagR* mutant background and could be directly related to GlcNAc metabolism, since it encodes a protein 52% similar to *N*-acetylglucosamine transferase PgaC of *Actinobacillus pleuropneumoniae*, responsible for the synthesis of poly-β-1,6-*N*-acetyl-D-glucosamine (9). Such polymeric substances, called polysaccharide intercellular adhesin (PIA), which can be partly deacetylated, are major components of bacterial biofilms in diverse eubacteria (20). One can speculate that inactivation of *nagR* would mimic signaling abundance of GlcNAc, which in turn would activate expression of genes for PIA synthesis. Interestingly, this coincides with the activation of the pyrimidine biosynthesis path-

way in mutant FT20 (average, 2.5-fold upregulated), which leads to UTP, which is used to activate GlcNAc-1-P via GlmU, the UDP-*N*-acetylglucosamine diphosphorylase. The generated UDP-GlcNAc-1-P is used for anabolic purposes, such as cell wall biosynthesis or PIA-dependent biofilm formation.

Another important gene of group 2 is *cggR*, the central glycolytic gene repressor, controlling expression of the five downstream genes of its operon, namely, *gapA*, *pgk*, *tpi*, *pgm*, and *eno*, gathering the steps of interconversion of the triose phosphates from dihydroxyacetone phosphate to phosphoenolpyruvate (17). The repressor activity of CggR is inhibited by fructose-1,6-biphosphate (FBP) resulting from phosphorylation of Fru-6-P by phosphofructokinase (*pfk*). Pfk enzymatic activity is a paradigm of allosteric regulation, where the intracellular pool of its substrate Fru-6-P plays a crucial regulatory role. Fru-6-P is generated by NagB from GlcN-6-P. We demonstrated in this study that the deletion of *nagR* results in NagB overproduction, which would increase the intracellular pool of FBP by allosteric activation of Pfk due to an excess of Fru-6-P. The overload of FBP would abolish the DNA-binding activity of CggR, which would prevent repression of its own expression, explaining the 3.5-fold upregulation in the  $\Delta yvoA$  mutant. Surprisingly, downstream genes of the *cggR* operon do not exhibit significant changes in their expression pattern, probably due to a complex and multiple level of control of this operon, as reported earlier (31, 32, 37).

Genes of group 3, downregulated in the  $\Delta nagR$  strain without apparent cognate binding sites, are estimated to be indirectly controlled, because HutC/GntR regulators like NagR are almost exclusively repressor proteins.

From the 31 genes in this category, the presence of the fumarate nitrate reductase regulator Fnr (14), required for the adaptation of *B. subtilis* to anaerobic conditions, required particular consideration. When grown under oxygen limitation, *B. subtilis* can use nitrate as a final electron acceptor (40), and this physiological adaptation requires Fnr. Fifteen other genes of group 3 belong to the Fnr regulon (Table 3), and these are as follows: (i) *narG*, *narH*, *narI*, *narJ*, and *narK*, involved in nitrate reduction and nitrate extrusion (25a), respectively; (ii) *dhbA*, *dhbB*, *dhbC*, *dhbE*, and *dhbF*, for siderophore bacillibactin synthesis (55); (iii) *ykuO* and *ykuP*, for flavodoxins involved in nitric oxide production (65); (iv) *cydC*, for the ABC transporter (ATP-binding component) for cytochrome *bd* production (67); (v) *arfM*, the anaerobic respiration and fermentation modulator; and (vi) *ydbN* (hypothetical protein). A plausible explanation for such a drastic repression of the Fnr regulon could be the nature of the end products of GlcNAc catabolism produced by NagA and NagB, which are overexpressed in the  $\Delta nagR$  mutant. Indeed, acetate,  $\text{NH}_3$ , and Fru-6-P are very strong signals of efficient catabolism requiring oxidative phosphorylation. We expect that the oxygen tension would be high and as a consequence the path for using nitrate as an alternative electron acceptor in anaerobic respiration would be severely repressed. This hypothesis is also supported by the downregulation of the *albE* and *albF* genes, involved in antibacterial subtilosin production (69), which in a wild-type background are induced in response to nutrient starvation and by oxygen limitation (41).

Some NagR-dependent genes of the Fnr regulon, namely, the *dhb* and *yku* operons as well as *cydC*, were previously

reported to also belong to the ferric uptake repressor (Fur) regulon (47), which controls the transcriptional response to iron starvation (3). Although expression of the *fur* gene itself is not strongly affected (1.4-fold upregulated in the *nagR* mutant), a total of 16 Fur-repressed genes were downregulated in strain FT20 (Table 3). The relationship between the Fnr and Fur regulons could be attributed to the inactivation of Fur repression by nitric oxide (NO), as reported for *Salmonella enterica* serovar Typhimurium (13). NO is thought to mimic or cause iron deficiency by complexing with free iron, leading to depletion of the cellular iron pool and subsequent activation of the Fur regulon. In the *nagR* mutant, the downregulation of Fnr would reduce intracellular amounts of NO. In turn, less ferric iron could be complexed by NO, so elevated intracellular levels of ferric iron would lead to formation of the Fe-Fur complex, which represses the iron starvation stimulon.

Finally, microarray data highlighted *nagR* mutant downregulated genes involved in carbohydrate transport (*ganQ* and *amyD*), spore engulfment (*spoIIQ*), biotin uptake (*bioYB*), or aldehyde dehydrogenation (*dhaS*) or with unknown function (*yjdB*), but their association to any GlcNAc-related process is too speculative to generate discussion. Of note, the methionine aminopeptidase-encoding gene *yflG*, previously reported as moderately controlled by NagR (68), did not match our criteria of an expression profile in strain FT20 significantly different from that in the parental strain based upon our microarray data.

**Conclusions.** So far, the mode of control of GlcNAc uptake and metabolism in *B. subtilis* has been considerably less well analyzed than is the case for *E. coli* (2) and the Gram-positive high-G+C model bacterium *S. coelicolor* (43, 51). According to earlier work and to data presented here, the current knowledge on GlcNAc-dependent pathways in *B. subtilis* is summarized in Fig. 6. NagR represses expression of the three GlcNAc-inducible genes *nagA*, *nagB*, and *nagP* by directly binding a 16-bp sequence identified within their upstream regions, and this interaction is abolished upon GlcN-6-P binding to the regulator. The verification of connections highlighted from our microarray data between NagR and major regulatory proteins of *B. subtilis*, such as Fnr, Fur, and CggR—and their associated biological processes—requires further experimental support.

The result of the computational prediction of full-length NagR-binding sites indicated that these are found only scarcely in the *B. subtilis* genome, which strongly suggests indirect regulation by end products of GlcNAc hydrolysis rather than by NagR/*dre*-dependent direct *cis/trans* control. However, Resch and collaborators demonstrated that once bound to GlcNAc-6-P, NagR is still able to bind half-side *dre* *in vitro*. This is compatible with a model in which the regulator acts as both an activator and a repressor beyond the canonical mutually exclusive effector-bound or DNA-bound regulator logic (49). If GlcNAc-6-P should prove capable of inducing a jumping-jack-like motion of NagR (as proposed by Resch et al.) *in vivo* or if the NagR/GlcNAc-6-P complex is still able to recognize and bind half-side *dre*, this automatically raises the question of how widespread the distribution of half-NagR-binding sites in the *B. subtilis* chromosome is. A preliminary prediction of this 8-bp motif obviously gave reason to assume a much larger putative *dre* half-side-dependent NagR regulon, if this mode of control held true. Demonstration of how (and if) NagR could behave



as a repressor and activator depending on the nutritional context will require significant additional experiments, which are necessary for understanding the complex response to GlcNAc in *Bacillus* species.

#### ACKNOWLEDGMENTS

We thank Annette Kamionka for help with YvoA purification, Hildegard Stork for support with enzyme assays, Martina Kolb for cloning of *lacZ* fusions and measurements, and Anne Winter and Klaus Pfeleiderer for further technical support. Jörg Stülke is acknowledged for fruitful discussions and the gift of pAC7. We are grateful to Anne de Jong, Aldert Zomer, and Siger Holsappel for *in silico* work and array data evaluation and to Markus Resch for providing a template for Fig. 6.

This study was supported by the Deutsche Forschungsgemeinschaft through the Sonderforschungsbereich SFB 473 (Schaltvorgänge der Transkription) and through grant BE4038/1. S.R. is an F.R.S.-FNRS research associate.

#### REFERENCES

- Alice, A. F., G. Perez-Martinez, and C. Sanchez-Rivas. 2003. Phosphoenolpyruvate phosphotransferase system and *N*-acetylglucosamine metabolism in *Bacillus sphaericus*. *Microbiology* **149**:1687–1698.
- Alvarez-Anorve, L. I., M. L. Calcagno, and J. Plumbridge. 2005. Why does *Escherichia coli* grow more slowly on glucosamine than on *N*-acetylglucosamine? Effects of enzyme levels and allosteric activation of GlcN6P deaminase (NagB) on growth rates. *J. Bacteriol.* **187**:2974–2982.
- Baichoo, N., T. Wang, R. Ye, and J. D. Helmann. 2002. Global analysis of the *Bacillus subtilis* Fur regulon and the iron starvation stimulon. *Mol. Microbiol.* **45**:1613–1629.
- Bates, C. J., and C. A. Pasternak. 1965. Further studies on the regulation of amino sugar metabolism in *Bacillus subtilis*. *Biochem. J.* **96**:147–154.
- Bertram, R., M. Kolb, and W. Hillen. 2009. In vivo activation of tetracycline repressor by Cre/*lox*-mediated gene assembly. *J. Mol. Microbiol. Biotechnol.* **17**:136–145.
- Bertram, R., M. Köstner, J. Müller, J. Vazquez Ramos, and W. Hillen. 2005. Integrative elements for *Bacillus subtilis* yielding tetracycline-dependent growth phenotypes. *Nucleic Acids Res.* **33**:e153.
- Bhavsar, A. P., and E. D. Brown. 2006. Cell wall assembly in *Bacillus subtilis*: how spirals and spaces challenge paradigms. *Mol. Microbiol.* **60**:1077–1090.
- Blencke, H. M., et al. 2003. Transcriptional profiling of gene expression in response to glucose in *Bacillus subtilis*: regulation of the central metabolic pathways. *Metab. Eng.* **5**:133–149.
- Bossé, J. T., et al. 2010. Regulation of *pga* operon expression and biofilm formation in *Actinobacillus pleuropneumoniae* by sigmaE and H-NS. *J. Bacteriol.* **192**:2414–2423.
- Clarke, J. S., and C. A. Pasternak. 1962. The regulation of amino sugar metabolism in *Bacillus subtilis*. *Biochem. J.* **84**:185–191.
- Colson, S., et al. 2007. Conserved *cis*-acting elements upstream of genes composing the chitinolytic system of streptomycetes are DasR-responsive elements. *J. Mol. Microbiol. Biotechnol.* **12**:60–66.
- Colson, S., et al. 2008. The chitobiose-binding protein, DasA, acts as a link between chitin utilization and morphogenesis in *Streptomyces coelicolor*. *Microbiology* **154**:373–382.
- Crawford, M. J., and D. E. Goldberg. 1998. Regulation of the *Salmonella typhimurium* flavohemoglobin gene. A new pathway for bacterial gene expression in response to nitric oxide. *J. Biol. Chem.* **273**:34028–34032.
- Cruz Ramos, H., et al. 1995. Anaerobic transcription activation in *Bacillus subtilis*: identification of distinct FNR-dependent and -independent regulatory mechanisms. *EMBO J.* **14**:5984–5994.
- Dartois, V., A. Baulard, K. Schanck, and C. Colson. 1992. Cloning, nucleotide sequence and expression in *Escherichia coli* of a lipase gene from *Bacillus subtilis* 168. *Biochim. Biophys. Acta* **1131**:253–260.
- Dereeper, A., et al. 2008. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. *Nucleic Acids Res.* **36**:W465–W469.
- Doan, T., et al. 2003. The *Bacillus subtilis* *ywkA* gene encodes a malic enzyme and its transcription is activated by the YufL/YufM two-component system in response to malate. *Microbiology* **149**:2331–2343.
- Dobrogosz, W. J. 1968. Effect of amino sugars on catabolite repression in *Escherichia coli*. *J. Bacteriol.* **95**:578–584.
- Ettner, N., et al. 1996. Fast large-scale purification of tetracycline repressor variants from overproducing *Escherichia coli* strains. *J. Chromatogr. A* **742**:95–105.
- Flemming, H. C., and J. Wingender. 2010. The biofilm matrix. *Nat. Rev. Microbiol.* **8**:623–633.
- Geissendörfer, M., and W. Hillen. 1990. Regulated expression of heterologous genes in *Bacillus subtilis* using the Tn10 encoded tet regulatory elements. *Appl. Microbiol. Biotechnol.* **33**:657–663.
- Görke, B., and J. Stülke. 2008. Carbon catabolite repression in bacteria: many ways to make the most out of nutrients. *Nat. Rev. Microbiol.* **6**:613–624.
- Hanahan, D. 1983. Studies on transformation of *Escherichia coli* with plasmids. *J. Mol. Biol.* **166**:557–580.
- Hiard, S., et al. 2007. PREDetector: a new tool to identify regulatory elements in bacterial genomes. *Biochem. Biophys. Res. Commun.* **357**:861–864.
- Hobl, B., and M. Mack. 2007. The regulator protein PyrR of *Bacillus subtilis* specifically interacts *in vivo* with three untranslated regions within *pyr* mRNA of pyrimidine biosynthesis. *Microbiology* **153**:693–700.
- Hoffmann, T., B. Troup, A. Szabo, C. Hungerer, and D. Jahn. 1995. The anaerobic life of *Bacillus subtilis*: cloning of the genes encoding the respiratory nitrate reductase system. *FEMS Microbiol. Lett.* **131**:219–225.
- Kamionka, A., R. Bertram, and W. Hillen. 2005. Tetracycline-dependent conditional gene knockout in *Bacillus subtilis*. *Appl. Environ. Microbiol.* **71**:728–733.
- Kraus, A., C. Hueck, D. Gärtner, and W. Hillen. 1994. Catabolite repression of the *Bacillus subtilis* *xyl* operon involves a *cis* element functional in the context of an unrelated sequence, and glucose exerts additional *xylR*-dependent repression. *J. Bacteriol.* **176**:1738–1745.
- Lammers, C. R., et al. 2010. Connecting parts with processes: SubtiWiki and SubtiPathways integrate gene and pathway annotation for *Bacillus subtilis*. *Microbiology* **156**:849–859.
- Leibig, M., et al. 2008. Marker removal in staphylococci via Cre recombinase and different *lox* sites. *Appl. Environ. Microbiol.* **74**:1316–1323.
- Londono-Vallejo, J. A., C. Frehel, and P. Stragier. 1997. SpoIIQ, a forespore-expressed gene required for engulfment in *Bacillus subtilis*. *Mol. Microbiol.* **24**:29–39.
- Ludwig, H., et al. 2001. Transcription of glycolytic genes and operons in *Bacillus subtilis*: evidence for the presence of multiple levels of control of the *gapA* operon. *Mol. Microbiol.* **41**:409–422.
- Ludwig, H., N. Rebhan, H. M. Blencke, M. Merzbacher, and J. Stülke. 2002. Control of the glycolytic *gapA* operon by the catabolite control protein A in *Bacillus subtilis*: a novel mechanism of CcpA-mediated regulation. *Mol. Microbiol.* **45**:543–553.
- Lulko, A. T., G. Buist, J. Kok, and O. P. Kuipers. 2007. Transcriptome analysis of temporal regulation of carbon metabolism by CcpA in *Bacillus subtilis* reveals additional target genes. *J. Mol. Microbiol. Biotechnol.* **12**:82–95.
- Mack, D., et al. 1996. The intercellular adhesin involved in biofilm accumulation of *Staphylococcus epidermidis* is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis. *J. Bacteriol.* **178**:175–183.
- Marino, M., H. C. Ramos, T. Hoffmann, P. Glaser, and D. Jahn. 2001. Modulation of anaerobic energy metabolism of *Bacillus subtilis* by *arfM* (*ywiD*). *J. Bacteriol.* **183**:6815–6821.
- Martin-Verstraete, I., J. Stülke, A. Klier, and G. Rapoport. 1995. Two different mechanisms mediate catabolite repression of the *Bacillus subtilis* levanase operon. *J. Bacteriol.* **177**:6919–6927.
- Meinken, C., H. M. Blencke, H. Ludwig, and J. Stülke. 2003. Expression of the glycolytic *gapA* operon in *Bacillus subtilis*: differential syntheses of proteins encoded by the operon. *Microbiology* **149**:751–761.
- Miller, J. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- Mobley, H. L., R. J. Doyle, U. N. Streips, and S. O. Langemeier. 1982. Transport and incorporation of *N*-acetyl-D-glucosamine in *Bacillus subtilis*. *J. Bacteriol.* **150**:8–15.
- Nakano, M. M., Y. P. Dailly, P. Zuber, and D. P. Clark. 1997. Characterization of anaerobic fermentative growth of *Bacillus subtilis*: identification of fermentation end products and genes required for growth. *J. Bacteriol.* **179**:6749–6755.
- Nakano, M. M., G. Zheng, and P. Zuber. 2000. Dual control of *sbo-alb* operon expression by the Spo0 and ResDE systems of signal transduction under anaerobic conditions in *Bacillus subtilis*. *J. Bacteriol.* **182**:3274–3277.
- Nothaft, H., et al. 2003. The phosphotransferase system of *Streptomyces coelicolor* is biased for *N*-acetylglucosamine metabolism. *J. Bacteriol.* **185**:7019–7023.
- Nothaft, H., et al. 2010. The permease gene *nagE2* is the key to *N*-acetylglucosamine sensing and utilization in *Streptomyces coelicolor* and is subject to multi-level control. *Mol. Microbiol.* **75**:1133–1144.
- Parche, S., R. Schmid, and F. Titgemeyer. 1999. The phosphotransferase system (PTS) of *Streptomyces coelicolor* identification and biochemical analysis of a histidine phosphocarrier protein HPr encoded by the gene *ptsH*. *Eur. J. Biochem.* **265**:308–317.
- Plumbridge, J. 2001. Regulation of PTS gene expression by the homologous transcriptional regulators, Mlc and NagC, in *Escherichia coli* (or how two similar repressors can behave differently). *J. Mol. Microbiol. Biotechnol.* **3**:371–380.
- Pomerantsev, A. P., R. Sitaraman, C. R. Galloway, V. Kivovich, and S. H. Leppla. 2006. Genome engineering in *Bacillus anthracis* using Cre recombinase. *Infect. Immun.* **74**:682–693.
- Reents, H., R. Münch, T. Dammeyer, D. Jahn, and E. Hartig. 2006. The Fnr regulon of *Bacillus subtilis*. *J. Bacteriol.* **188**:1103–1112.

48. Reizer, J., et al. 1999. Novel phosphotransferase system genes revealed by genome analysis—the complete complement of PTS proteins encoded within the genome of *Bacillus subtilis*. *Microbiology* **145**(Pt. 12):3419–3429.
49. Resch, M., E. Schiltz, F. Titgemeyer, and Y. A. Muller. 2010. Insight into the induction mechanism of the GntR/HutC bacterial transcription regulator YvoA. *Nucleic Acids Res.* **38**:2485–2497.
50. Rigali, S., A. Derouaux, F. Giannotta, and J. Dusart. 2002. Subdivision of the helix-turn-helix GntR family of bacterial regulators in the FadR, HutC, MocR, and YtrA subfamilies. *J. Biol. Chem.* **277**:12507–12515.
51. Rigali, S., et al. 2006. The sugar phosphotransferase system of *Streptomyces coelicolor* is regulated by the GntR-family regulator DasR and links *N*-acetylglucosamine metabolism to the control of development. *Mol. Microbiol.* **61**:1237–1251.
52. Rigali, S., et al. 2004. Extending the classification of bacterial transcription factors beyond the helix-turn-helix motif as an alternative approach to discover new *cis/trans* relationships. *Nucleic Acids Res.* **32**:3418–3426.
53. Rigali, S., et al. 2008. Feast or famine: the global regulator DasR links nutrient stress to antibiotic production by *Streptomyces*. *EMBO Rep.* **9**:670–675.
54. Robinson, C., C. Rivolta, D. Karamata, and A. Moir. 1998. The product of the *yvoC* (*gerF*) gene of *Bacillus subtilis* is required for spore germination. *Microbiology* **144**(Pt. 11):3105–3109.
55. Rowland, B. M., T. H. Grossman, M. S. Osburne, and H. W. Taber. 1996. Sequence and genetic organization of a *Bacillus subtilis* operon encoding 2,3-dihydroxybenzoate biosynthetic enzymes. *Gene* **178**:119–123.
56. Sadaie, Y., H. Nakadate, R. Fukui, L. M. Yee, and K. Asai. 2008. Glucosaminan utilization operon of *Bacillus subtilis*. *FEMS Microbiol. Lett.* **279**:103–109.
57. Saier, M. H., Jr., et al. 2002. Transport capabilities encoded within the *Bacillus subtilis* genome. *J. Mol. Microbiol. Biotechnol.* **4**:37–67.
58. Satomura, T., et al. 2005. Enhancement of glutamine utilization in *Bacillus subtilis* through the GlnK-GlnL two-component regulatory system. *J. Bacteriol.* **187**:4813–4821.
59. Schau, M., A. Eldakak, and F. M. Hulett. 2004. Terminal oxidases are essential to bypass the requirement for ResD for full Pho induction in *Bacillus subtilis*. *J. Bacteriol.* **186**:8424–8432.
60. Schöck, F., and M. K. Dahl. 1996. Expression of the *tre* operon of *Bacillus subtilis* 168 is regulated by the repressor TreR. *J. Bacteriol.* **178**:4576–4581.
61. Simoni, R. D., S. Roseman, and M. H. Saier, Jr. 1976. Sugar transport. Properties of mutant bacteria defective in proteins of the phosphoenolpyruvate:sugar phosphotransferase system. *J. Biol. Chem.* **251**:6584–6597.
62. Stülke, J., and W. Hillen. 2000. Regulation of carbon catabolism in *Bacillus* species. *Annu. Rev. Microbiol.* **54**:849–880.
63. Vincent, F., G. J. Davies, and J. A. Brannigan. 2005. Structure and kinetics of a monomeric glucosamine 6-phosphate deaminase: missing link of the NagB superfamily? *J. Biol. Chem.* **280**:19649–19655.
64. Vincent, F., D. Yates, E. Garman, G. J. Davies, and J. A. Brannigan. 2004. The three-dimensional structure of the *N*-acetylglucosamine-6-phosphate deacetylase, NagA, from *Bacillus subtilis*: a member of the urease superfamily. *J. Biol. Chem.* **279**:2809–2816.
65. Wang, Z. Q., et al. 2007. Bacterial flavodoxins support nitric oxide production by *Bacillus subtilis* nitric-oxide synthase. *J. Biol. Chem.* **282**:2196–2202.
66. Weinrauch, Y., T. Msadek, F. Kunst, and D. Dubnau. 1991. Sequence and properties of *comQ*, a new competence regulatory gene of *Bacillus subtilis*. *J. Bacteriol.* **173**:5685–5693.
67. Winstedt, L., K. Yoshida, Y. Fujita, and C. von Wachenfeldt. 1998. Cytochrome *bd* biosynthesis in *Bacillus subtilis*: characterization of the *cydABCD* operon. *J. Bacteriol.* **180**:6571–6580.
68. You, C., et al. 2005. The two authentic methionine aminopeptidase genes are differentially expressed in *Bacillus subtilis*. *BMC Microbiol.* **5**:57.
69. Zheng, G., L. Z. Yan, J. C. Vederas, and P. Zuber. 1999. Genes of the *sbo-alb* locus of *Bacillus subtilis* are required for production of the antilisterial bacteriocin subtilisin. *J. Bacteriol.* **181**:7346–7355.